Get the Stockscreener App
9.78
1.77%
0.17
Alpha Tau Medical Ltd stock is traded at $9.78, with a volume of 572.74K.
It is up +1.77% in the last 24 hours and down -2.49% over the past month.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
See More
Previous Close:
$9.61
Open:
$9.8
24h Volume:
572.74K
Relative Volume:
0.84
Market Cap:
$883.39M
Revenue:
-
Net Income/Loss:
$-56.88M
P/E Ratio:
-14.81
EPS:
-0.6604
Net Cash Flow:
$-39.43M
1W Performance:
+1.03%
1M Performance:
-2.49%
6M Performance:
+95.21%
1Y Performance:
+236.07%
1-Day Range:
$9.45
$10.20
1-Week Range:
$9.21
$10.20
52-Week Range:
$2.85
$11.62
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Compare DRTS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
9.78 | 883.39M | 0 | -56.88M | -39.43M | -0.6604 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-26 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Apr-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-22 | Initiated | Piper Sandler | Overweight |
| Apr-04-22 | Initiated | Citigroup | Buy |
View All
Alpha Tau Medical Ltd Stock (DRTS) Latest News
Alpha Tau Medical Ltd (DRTSW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alpha Tau Medical Ltd (DRTSW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alpha Tau Medical Ltd (DRTSW) Institutional Confidence - TradingKey
Alpha Tau Medical Ltd (DRTSW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alpha Tau Medical Ltd (DRTS) Institutional Confidence - TradingKey
Alpha Tau Medical Ltd (DRTS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alpha Tau Medical Ltd (DRTS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alpha Tau Medical Ltd (DRTS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alpha Tau Medical Ltd (DRTS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Alpha Tau Medical Ltd (DRTSW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alpha Tau Medical Ltd (DRTSW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Alpha Tau Medical Ltd (DRTSW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
H.C. Wainwright reiterates Alpha Tau Medical stock rating on FDA trial clearance - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Alpha Tau Medical: A Lot Of Shots On Goal (NASDAQ:DRTS) - Seeking Alpha
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control - The Manila Times
Alpha Tau (NASDAQ: DRTS) gets FDA clearance to complete REGAIN glioblastoma trial enrollment - Stock Titan
Brain cancer trial sees 100% local control as FDA lets Alpha Tau treat patients - Stock Titan
Alpha Tau Medical sets up catalyst-rich 2026 as key cancer trial data nears - MSN
Barclays Maintains Alpha Tau Medical(DRTS.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Insider Sell: Raphi Levy Sells 32,500 Shares of Alpha Tau Medica - GuruFocus
Alpha Tau Medical (DRTS) CFO Levy Raphi sells 32,500 shares in open-market trades - Stock Titan
Alpha Tau,Tolmar Team Up to Bring Alpha DaRT Therapy to U.S. Prostate Cancer Patients - Imaging Technology News
[144] Alpha Tau Medical Ltd. SEC Filing - Stock Titan
Alpha Tau Medical and Tolmar partner to commercialise Alpha DaRT prostate cancer therapy in the US - Health Tech World
H.C. Wainwright Maintains Alpha Tau Medical(DRTS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Alpha Tau Medical Rises on Tolmar Deal to Commercialize Prostate Cancer Therapy - Moomoo
Alpha Tau teams with Tolmar on lucrative prostate cancer dealGlobes - Globes - Israel Business News
DRTS Stock Shot Up A Whopping 22% Today – Why A $196.5M Prostate Cancer Deal Got Investors Buzzing - Yahoo Finance
Alpha Tau Medical, Tolmar International Agree to Develop, Commercialize Prostate Cancer Therapy - Moomoo
Alpha Tau Strikes 20-Year U.S. Prostate Cancer Commercialization and $20 Million Equity Deal With Tolmar - TipRanks
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients - The Manila Times
Alpha Tau (DRTS) lands Tolmar partnership with $20M equity and milestones - Stock Titan
Alpha Tau and Tolmar Announce Strategic Collaboration to - GlobeNewswire
H.C. Wainwright reiterates Alpha Tau Medical stock rating on trial data - Investing.com UK
Number of shareholders of Alpha Tau Medical Ltd. – NASDAQ:DRTSW - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Barclays Maintains Alpha Tau Medical(DRTS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Alpha Tau Medical Reports Data Showing Alpha DaRT Increases Overall Survival for Patients With Pancreatic Cancer - Moomoo
Alpha Tau Posts Strong Pancreatic Cancer Survival Data for Alpha DaRT at 2026 ASCO - TipRanks
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting - The Manila Times
Alpha Tau trial links one-time pancreatic treatment to 11‑month survival - Stock Titan
Pancreatic survival data highlight Alpha Tau (NASDAQ: DRTS) Alpha DaRT trials - Stock Titan
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears - Yahoo Finance
DRTS Initiated Coverage by BarclaysRating Overweight with Tar - GuruFocus
DRTSW Holds Above Key Support After Modest DeclineWatchlist Stock Ideas - The Legal Advocate
DRTS: Key cancer trials advance with pivotal data expected in 2026; strong financial position maintained - TradingView
Barclays Initiates Alpha Tau Medical With Overweight Rating, $15 Price Target - marketscreener.com
Barclays initiates Alpha Tau Medical stock with overweight rating By Investing.com - Investing.com Nigeria
Barclays initiates Alpha Tau Medical stock with overweight rating - Investing.com
Alpha Tau Medical Ltd Stock (DRTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):